Literature DB >> 26503650

Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.

Peter Seiler1, Michel Enderlin-Paput2, Philippe Pfaff2, Maria Weiss2, Daniel Ritz2, Martine Clozel2, Hans H Locher2.   

Abstract

The promotion of colonization with vancomycin-resistant enterococci (VRE) is one potential side effect during treatment of Clostridium difficile-associated diarrhea (CDAD), resulting from disturbances in gut microbiota. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile and against VRE and is currently in clinical development for the treatment of CDAD. We report that CDZ treatment did not lead to intestinal VRE overgrowth in mice.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26503650      PMCID： PMC4704215          DOI： 10.1128/AAC.01923-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: recognition and prevention in intensive care units.

Authors:  Michael Y Lin; Mary K Hayden
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

2.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 3.  Vancomycin-resistant enterococci: colonization, infection, detection, and treatment.

Authors:  Ali Zirakzadeh; Robin Patel
Journal:  Mayo Clin Proc       Date:  2006-04       Impact factor: 7.616

4.  Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease.

Authors:  Ajay K Sethi; Wafa N Al-Nassir; Michelle M Nerandzic; Curtis J Donskey
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

Review 5.  Vancomycin-resistant enterococci (VRE): transmission and control.

Authors:  Evelina Tacconelli; Maria A Cataldo
Journal:  Int J Antimicrob Agents       Date:  2007-12-31       Impact factor: 5.283

6.  The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients.

Authors:  Cassandra D Salgado
Journal:  Am J Infect Control       Date:  2008-12       Impact factor: 2.918

7.  Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci.

Authors:  V Sakka; S Tsiodras; L Galani; A Antoniadou; M Souli; I Galani; M Pantelaki; N Siafakas; L Zerva; H Giamarellou
Journal:  Clin Microbiol Infect       Date:  2007-11-13       Impact factor: 8.067

8.  A mouse model of Clostridium difficile-associated disease.

Authors:  Xinhua Chen; Kianoosh Katchar; Jeffrey D Goldsmith; Nanda Nanthakumar; Adam Cheknis; Dale N Gerding; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-09-10       Impact factor: 22.682

9.  Health and economic outcomes of vancomycin-resistant enterococci.

Authors:  Yehuda Carmeli; George Eliopoulos; Essy Mozaffari; Matthew Samore
Journal:  Arch Intern Med       Date:  2002-10-28

10.  A prospective study of the impact of colonization following hospital admission by glycopeptide-resistant Enterococci on mortality during a hospital outbreak.

Authors:  Alexis Hautemanière; Paul R Hunter; Nathalie Diguio; Elaine Albuisson; Philippe Hartemann
Journal:  Am J Infect Control       Date:  2009-06-24       Impact factor: 2.918
View more
  5 in total

1.  Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.

Authors:  Haroon Mohammad; Ahmed AbdelKhalek; Nader S Abutaleb; Mohamed N Seleem
Journal:  Int J Antimicrob Agents       Date:  2018-02-09       Impact factor: 5.283

Review 2.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

3.  Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.

Authors:  Ahmed AbdelKhalek; Nader S Abutaleb; Khalifa A Elmagarmid; Mohamed N Seleem
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

Review 4.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

5.  Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo.

Authors:  George A Naclerio; Nader S Abutaleb; Daoyi Li; Mohamed N Seleem; Herman O Sintim
Journal:  J Med Chem       Date:  2020-10-06       Impact factor: 8.039
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.